NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Screening for Dyslipidemia in Younger Adults
Evidence Syntheses, No. 138
Investigators: Roger Chou, MD, Tracy Dana, MLS, Ian Blazina, MPH, Monica Daeges, BA, Christina Bougatsos, MPH, and Thomas Jeanne, MD.
Author Information and AffiliationsStructured Abstract
Background:
This review updates prior reviews on screening for lipid disorders in adults, and will be used by the U.S. Preventive Services Task Force (USPSTF) to update its 2008 recommendation. Unlike prior USPSTF reviews, this one focuses on screening in younger adults, defined as adults ages 21 to 39 years, as there is more uncertainty about the need to perform lipid screening in this population than in older adults.
Data Sources:
We searched the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Ovid MEDLINE from 2008 through May 2016 and manually reviewed reference lists.
Study Selection:
Two investigators independently reviewed the literature for studies on screening for and treatment of dyslipidemia in asymptomatic adults ages 21 to 39 years, including randomized, controlled trials, case-control studies, cohort studies, and good-quality systematic reviews.
Results:
No study evaluated the effects of lipid screening versus no screening, treatment versus no treatment, or delayed versus earlier treatment on clinical outcomes in younger adults. In addition, no study evaluated the diagnostic yield of alternative screening strategies in younger adults (e.g., targeted screening of persons with a family history of hyperlipidemia vs. general screening). Longitudinal studies suggest that lipid levels have a tendency to increase over time in younger adults, though no study evaluated how lipid levels change according to different intervals between repeat testing or the proportion of patients who would move from one risk category to another.
Limitations:
Lack of direct evidence in younger adults.
Conclusions:
Direct evidence on benefits and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable.
Contents
- Acknowledgements
- 1. Introduction
- Purpose and Previous U.S. Preventive Services Task Force Recommendation
- Condition Definition
- Prevalence and Burden of Disease/Illness
- Etiology and Natural History
- Risk Factors
- Rationale for Screening/Screening Strategies
- Interventions/Treatment
- Current Clinical Practice in the United States
- Recommendations of Other Groups
- 2. Methods
- 3. Results
- Key Question 1. What Are the Benefits of Screening for Dyslipidemia in Asymptomatic Adults Ages 21 to 39 Years on CHD- or CVA-Related Morbidity or Mortality or All-Cause Mortality?
- Key Question 2. What Are the Harms of Screening for Dyslipidemia in Asymptomatic Adults Ages 21 to 39 Years?
- Key Question 3. What Is the Diagnostic Yield of Alternative Screening Strategies for Dyslipidemia in Asymptomatic Adults Ages 21 to 39 Years?
- Key Question 4. What Are the Benefits of Treatment in Adults Ages 21 to 39 Years on CHD- or CVA-Related Morbidity or Mortality or All-Cause Mortality?
- Key Question 5. What Are the Benefits of Delayed Versus Immediate Treatment in Adults Ages 21 to 39 Years With Dyslipidemia on CHD- or CVA-Related Morbidity or Mortality or All-Cause Mortality?
- Key Question 6. What Are the Harms of Drug Treatment of Dyslipidemia in Asymptomatic Adults Ages 21 to 39 Years?
- Contextual Question 1. What Are the Benefits of Drug Treatment in Adults Ages 21 to 39 Years on Intermediate Outcomes?
- Contextual Question 2. How Do Lipid Levels Change Over Time in Adults Ages 21 to 39 Years?
- 4. Discussion
- References
- Appendix A. Detailed Methods
Suggested citation:
Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne T. Screening for Dyslipidemia in Younger Adults: A Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 138. AHRQ Publication No. 14-05206-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-290-2012-00015-I, Task Order No. 2). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
- 1
5600 Fishers Lane, Rockville, MD 20857; www
.ahrq.gov - 2
Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239; www
.ohsu.edu/epc
- NLM CatalogRelated NLM Catalog Entries
- Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP. 2016 Aug
- Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E. 2016 Aug
- Review Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2014]Review Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task ForcePiper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Smith N, Webber E, Perdue LA, Bigler KD, Whitlock EP. 2014 Dec
- Review Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task ForceWernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. 2016 Jul
- Review Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation[ 2012]Review Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force RecommendationChou R, Selph S, Dana T, Bougatsos C, Zakher B, Blazina I, Korthuis PT. 2012 Nov
- Screening for Dyslipidemia in Younger AdultsScreening for Dyslipidemia in Younger Adults
Your browsing activity is empty.
Activity recording is turned off.
See more...